Please assess the completion status of the following clinical trial:

Trial Title: A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Reasonably healthy men and women aged 50 to 75~Exclusion Criteria:~* History of abnormal bleeding, active bleeding or risk factors for bleeding~* History of thrombosis or risk factors for thrombosis~* History of adult asthma or use of inhaled medications

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Andexanet (Type: EXPERIMENTAL): Andexanet (antidote)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).